Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02471378|
Recruitment Status : Recruiting
First Posted : June 15, 2015
Last Update Posted : March 3, 2020
- Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away. Children younger than 5 and pregnant women are most at risk to get malaria. Researchers want to create a vaccine that will prevent malaria infection during pregnancy.
- To create a vaccine that will prevent malaria infection during pregnancy. To assess possible vaccines using in-vitro tests with parasites taken from pregnant women.
- Pregnant women ages 15 25
- The study site is an area in Mali, West Africa.
- Will have blood drawn.
- Will give consent for the blood sample to be used for future research.
- May have a physical exam.
- Participants who have malaria or anemia will get treatment.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||4791 participants|
|Official Title:||In-Vitro Testing of Pregnancy Malaria Vaccine Candidates|
|Actual Study Start Date :||July 28, 2015|
|Estimated Primary Completion Date :||June 30, 2021|
|Estimated Study Completion Date :||June 30, 2021|
Pregnant Women 15-25 years old
Malaria-infected pregnant Women
- Measure of functional activity of animal IgG against vaccine candidates to block binding of fresh pregnancy malaria isolates to the placental receptor CSA [ Time Frame: Approximately 1 year ]
- Measurement of parasite density in the in-vitro binding inhibition assay [ Time Frame: Approximately 1 year ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02471378
|Contact: Michal Fried, Ph.D.||(301) firstname.lastname@example.org|
|Ouelessebougou Clinical Research Center||Recruiting|
|Principal Investigator:||Michal Fried, Ph.D.||National Institute of Allergy and Infectious Diseases (NIAID)|